Pfizer Inc
PFE-
Pfizer Inc. decreased 0.6% to $30.39 after the drugmaker recorded charges related to its COVID vaccine and COVID antiviral treatment Paxlovid.
The company took a $5.6 billion inventory write-down in the third quarter related to COVID products.
Revenue in the third quarter plunged 42% to $13.2 billion from $22.6 billion, and the company swung to a net loss of $2.4 billion from a profit of $8.6 billion, and diluted earnings per share declined to ($0.42) from $1.54 a year ago.
The pharmaceutical company guided full-year 2023 revenue to decline between 39% and 42% from a year ago, primarily because of the lower demand for COVID products.
Oct 31, 2023 -
Pfizer Inc gained 4.5% to $33.69 after the pharmaceutical company lowered its annual revenue guidance.
Pfizer revised lower its 2023 revenue in the range between $58 billion and $61 billion, from the previous estimate between $67 billion and $70 billion on the weakening demand for its Covid products.
The company also lowered its full-year adjusted earnings per share outlook to a new range of $1.45 to $1.65 from the previous estimate between $3.25 and $3.45.
Oct 16, 2023 -
Pfizer Inc increased 0.9% to $36.27 after the pharmaceutical company reported mixed quarterly results in the second quarter.
Revenue in the second quarter declined 54% to $12.7 billion from $27.7 billion and net income plunged 77% to $2.3 billion from $9.9 billion and diluted earnings per share dropped to 41 cents from $1.43 a year ago.
Expected decline in Paxlovid and Comirnaty (Covid vaccine) revenues drove a 53% decline in operating revenues.
Aug 1, 2023 -
Pfizer Inc increased 1.1% to $39.61 after the company reported a sharp decline in revenue following the end of Covid-19 revenue.
Revenue in the first quarter decreased 29% to $18.2 billion from $25.6 billion and net income plunged 30% to $5.5 billion from $7.86 billion and diluted earnings per share fell to 97 cents from $1.37 a year ago.
The company reiterated its full-year 2023 outlook and forecasted revenue to fall between 29% and 33% or between $67.0 billion and $71.0 billion.
Excluding Covid-19 products, the company forecasted operating revenue to increase between 7% and 9%.
Pfizer also confirmed that it has not repurchased any of its shares and the company has no plan to buy back its own shares in the remainder of the year.
The company still has $3.3 billion available in its stock repurchase program.
May 3, 2023
|
|
| |
|
| Trading Volume | 1,421,230 |
|
|
35.79 - 25.37 |
| Market Cap Full | $ 162.2B |
Quarterly +
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Q1 | 1.7% | 0.1% | -3.7% | -20.5% |
| Q2 | - | -1% | 0.5% | -10.1% |
| Q3 | - | -1% | -6.1% | -9.5% |
| Q4 | - | -1% | 1.2% | -15.2% |
Monthly +
| J | F | M | A | M | J | J | A | S | O | N | D |
| 2026 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - |
| 2025 | |||||||||||
| 0.1 | - | - | - | - | - | - | - | - | - | - | - |
| 2024 | |||||||||||
| -6 | -1.9 | 4.5 | -6.5 | 10.8 | -3.2 | 10 | -6.1 | - | - | - | 1.3 |
| 2023 | |||||||||||
| -13.8 | -8.1 | 0.5 | -4.6 | -2.2 | -3.7 | -1.6 | -1.9 | -6.2 | -7.9 | -0.4 | -5.4 |
| 2022 | |||||||||||
| -11.1 | -11 | 10.3 | -5.2 | 8.1 | -1.2 | -3.7 | -9.9 | -4.7 | 6.4 | 8.6 | 2.2 |
| 2021 | |||||||||||
| -2.5 | -6.7 | 8.5 | 6.3 | 0.7 | 0.6 | 9.3 | 7.6 | -6.6 | 1.7 | 22.8 | 10.5 |
EPS
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Q1 | 1 | 1.4 | 0.9 |
| Q2 | 0.4 | 1.7 | 1 |
| Q3 | -0.4 | 1.5 | 1.4 |
| Q4 | 0 | 0.9 | 0.6 |
| A | 0.96 | 5.5 | 3.9 |